MedTrace Logo

Prospective Evaluation of Strontium in Patients After CardioGen-82 PET MPI Scanning at Two Clinical Sites

NCT01430975 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 72

Last updated 2012-04-25

No results posted yet for this study

Summary

This study is to be performed at two clinical sites where patients received CardioGen-82 during the time period January to June, 2011 and where patients were scanned chronologically near to the index patients (2 days before or after). Of these, it is planned that at least 30 patients will be entered in this trial. Index patient is the term applied to individuals who had radiation spectra indicative of Sr-82 and Sr-85 detected by hand-held survey meters.

Conditions

  • Radiation Exposure

Interventions

DRUG

CardioGen-82

CardioGen-82 was not administered as part of this trial but the patients enrolled had to have received CardioGen-82 previously

DRUG

CardioGen-82

Patients do not received CardioGen-82 as part of this study. To be in the study they would have had to receive CardioGen-82 previously.

Sponsors & Collaborators

  • Bracco Diagnostics, Inc

    lead INDUSTRY

Principal Investigators

  • Steven Sireci, M.D. · Bracco Diagnostics, Inc

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2012-03-31
Completion
2012-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01430975 on ClinicalTrials.gov